AmCad BioMed Corporation (AmCad) was founded in 2008 and was listed on Taipei Exchange in March of 2015 (Ticker: 4188). AmCad is dedicated to developing innovative Computer-Assisted Detection and Diagnosis (CAD) devices. Moreover, AmCad is committed to developing unique products that assist medical professionals in making more accurate early diagnoses. By integrating AI with innovative hardware solutions, we aim to solve long-standing unmet medical needs. We are bolstering clinicians expertise with AI-driven technology. Our patented algorithms provide medical professionals detailed quantification and visualization of sonographic characteristics. AmCad has successfully obtained numerous FDA 510(k) Clearances and CE Mark certifications for four products. AmCad's product lines include AmCAD-UT® (FDA, CE Mark, TFDA and CFDA, for thyroid cancer analysis), AmCAD-UO (FDA and CE Mark for obstructive sleep apnea detection), AmCAD-US (FDA and CE Mark for backscattered signals analysis), AmCAD-UV (FDA and CE Mark for classifying pulsatile signals and noise), and AmCAD-CA (Cytopathology analysis). The state-of-the-art pipeline aims for early detection and diagnosis of various diseases, such as thyroid cancers, fatty liver, liver fibrosis and obstructive sleep apnea.